Early growth response-1 (EGR-1) is considered a central regulator in tumor cell proliferation, migration and angiogenesis and a promising candidate for gene therapy in human astrocytomas. However, conflicting data have been reported suggesting that both tumor promoting and anti-tumor activity of EGR-1 and its regulation, expression and prognostic significance still remain enigmatic. Our study explored EGR-1 expression and regulation in astrocytomas and its association with patient survival. As we detected two EGR-1 mRNA variants, one containing a N-methyl-D-aspartate-receptor (NMDA-R) responsive cytoplasmic polyadenylation element (CPE), further experiments were performed to determine the functional role of this pathway. After NMDA stimulation of SV-FHAS and neoplastic astrocytes, real-time polymerase chain reaction showed an increase of the CPE, containing EGR-1 splice variant only in astrocytoma cells. The surface expression and functionality of NMDA-R were demonstrated by flow cytometric analysis and measurement of increased intracellular Ca(2+). EGR-1 was mainly restricted to tumor cells expressing NMDA-R and significantly up-regulated in astrocytic tumors compared with normal brain. Further, EGR-1 expression was significantly (P < 0.007) associated with enhanced patient survival and was an independent prognostic factor in multivariate analysis in high grade astrocytomas. The NMDA-R-mediated EGR-1 expression, therefore, seems to be a promising target for novel clinical approaches to astrocytoma treatment. 
Introduction
Despite improvement of surgical treatment and progress in radio-and chemotherapeutical strategies, the median survival times in diffuse astrocytomas remains as low as 1.6 years in anaplastic astrocytoma and only 0.4 years in glioblastoma (23) . The migratory and proliferative capacity of astrocytomas which is accused to be at least partly responsible for the poor prognosis might be associated with Ca 2+ permeable glutamate receptors (13, 20, 26) . Along those lines, glutamate levels in human gliomas correlate with the degree of cell proliferation (2) . Cellular mechanisms linking glutamate receptors to stimulation of migration and proliferation so far remain elusive but may include the immediate early gene EGR-1 ("early growth response-1"; also known as Krox24, Zif268, NGFI-A, Zenk, tis8, etr103 or d2) which is regulated upon glutamate receptor activation (5, 8, 30) . However, in tumor cells EGR-1 may both, stimulate and suppress malignant progression. In glioblastoma cell lines EGR-1 binds to GC-rich sites of the human TGF-beta1 promotor leading to decreased proliferation and suppressed transformation. At the same time tumor cell migration is stimulated via activation of fibronectin (4, 18) . In carcinoma cell lines, EGR-1 protein expression seems to be responsible for various features of tumor progression such as proliferation, migration, chemoinvasion and angiogenesis (7, 22, 23) . In contrast, sustained expression of EGR-1 in endothelial and fibrosarcoma cells blocks angiogenesis and tumor growth (19) . In glioma cell lines EGR-1 may downregulate cyclin D1 and may thus exert a tumor suppressing function (27) . In prostatic cancer, EGR-1 expression increases with the grade of malignancy (6) . In nephroblastomas enhanced EGR-1 expression is associated with an unfavourable clinical prognosis (9) . In contrast, in human breast and lung cancer, EGR-1 expression decreases with the grade of malignancy (11, 16) . Tumor suppressor capacity of EGR-1 is further suggested by (i) direct transactivation of the PTEN gene,
(ii) induction of p53 and (iii) binding of transcription factor c-Jun leading to increased pro-apoptotic activity (17, 32) . EGR-1 activation could be mediated by NMDA-R (Nmethyl D-aspartate-receptor) stimulation since the EGR-1 gene possesses two different potential NMDA-R-responsive cytoplasmic polyadenylation elements (CPE1 and CPE2) which are located close to the polyadenylation signal (HEX) (Figure 1 ) (29) . These CPEs are responsible for the post-transcriptional translation of mRNAs that probably belong to a dormant cytoplasmic mRNA pool (21, 33) . Signal transduction upon NMDA-R stimulation is mediated by the activation of the Aurora kinase which in turn phosphorylates the CPE binding protein (CPEB) which is required for a polyadenylation-dependent translation (12) . Until now it is not clear how EGR-1 expression is regulated and why it exerts a dual role in astrocytomas.
Further it remains to be established how the prognosis of astrocytomas may be related to the EGR-1 expression. In the present study, we therefore address the NMDA-R dependent regulation and prognostic impact of EGR-1 expression in human astrocytomas.
Materials and Methods

Cell culture and stimulation
The human glioblastoma cell lines LN229, LN428, U158, U251, U373 (kindly provided by N. 
Primary glioblastoma cell culture
Ex vivo glioma cell cultures, passages 4 to 9 of 5 glioblastoma patients were generated after tumour resection at the University Hospital of Zürich as previously described (24) . All procedures were conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the Canton Zürich. The diagnoses were confirmed at the Institute of Neuropathology, University Hospital of Zürich.
Real-time RT-PCR:
Total RNA was harvested from the tissue culture cells by using Trizol Reagent®.
Consecutively, 1 µg of every RNA sample was reverse-transcribed using Superscript II® in the same run. PCR was performed with standard protocols using SYBRGreen® 
Flow cytometry
Glioma cell lines and primary glioblastoma cells were analyzed for the expression of NMDA-R 1, the key receptor subunit of the heteromeric NMDA-R using flow 
Patients and tissues
We (range 1-136). 13 patients were lost to follow-up immediately after operation, so this population could not be integrated into the Kaplan-Meier survival analysis. For agestratified groups, patients were divided by median split. In the group of pilocytic astrocytomas only one patient died during the time of observation, therefore WHO grade I astrocytomas were not taken into account for survival analysis.
Tissue microarray (TMA)
TMA composite paraffin blocks were constructed by extracting cylindrical tissue core biopsies from different paraffin donor blocks and re-embedding these into a prepunched hole on a single recipient (microarray) paraffin block at defined array coordinates (15) . Using this technique, representative tissue sections were extracted and prepared as TMA (Beecher Instruments, Inc., Sun Prairie; WI, USA) with a core diameter of 600 µm. Prior to this TMA construction a hematoxylin & eosin (HE) stained slide of each block was analyzed to avoid inappropriate regions (e.g. necrosis, hemorrhage) on the TMA slides. The TMA blocks were then cut with a microtome (3 µm thickness) and placed on SuperFrost Plus slides (Microm International, Walldorf, Germany).
Immunohistochemistry
All specimens were fixed in 4% formalin (pH 7.4), embedded in paraffin followed by preparation as TMA. Immunohistochemical stainings were performed according to standard protocols. The following primary antibodies were used: rabbit polyclonal anti-Egr1 against the carboxy terminus (dilution: 1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) followed by a biotinylated secondary anti-rabbit F(ab')2 fragments (DAKO Cytomation, Hamburg, Germany). Exemplarily, double labeling was performed with Dako EnVision using DAB (1:500; GFAP; dilution: 1:500;
Chemicon, Temecula, CA, USA) and Fast Red (EGR-1) as chromogens. For controls, the primary antibodies were omitted.
Light microscopy and counting
Evaluation of the immunohistochemical stainings and photographic documentation (dilution: 1:50) and Cy3 (1:100) were purchased from Dianova (Hamburg, Germany).
Following washes in TBS, nuclei of the glioma cells were stained with SYTOX green (dilution 1:1000; Invitrogen, Karlsruhe, Germany). After further washes in TBS, glass slides were mounted in glycerol. For controls, the primary antibodies were omitted.
Fluorescence was visualized with a confocal laser scanning microscope (Axiovert 135M, Zeiss, Oberkochen, Germany) and images were processed using Adobe Photoshop (version 6.0, Adobe, Mountain View, CA, USA).
Statistical analysis
For the analysis of PCR data, we processed the raw data CT values by calculating mean normalized expression (MNE) values which reflect the relative expression of a target to the housekeeping gene (28) . Statistical analysis was performed using a pair wise fixed allocation randomization test® which has particularly been designed for the evaluation of quantitative real-time PCR results. The average coefficient of variation of the triplicates was 12%. Accordingly, a difference of more than 55%
between two samples had a statistical power of 95%. We therefore only assigned significance to differences which were greater than 55%. The significance levels were the following: p < 0.05 (*); p< 0.01 (**); p < 0.001 (***). 
Results
Predominantly CPE-containing EGR-1 variants increase upon NMDA stimulation
Under non-activating conditions the expression of Egr-1sv (short variant) is about 5-fold higher than the expression of Egr-1lv (long variant) (Figure 1, 2) in both the malignant glioma cell line LN229 and the immortalized astrocytic cell line SV-FHAS.
After 10 min treatment with NMDA only the glioma cell line LN229 showed a significant 8.6-fold induction of Egr-1lv and a less pronounced 2.2-fold induction of Egr-1sv (Figure 2) . While Egr-1lv still showed a significant 3.3-fold increase at 30 min, Egr-1sv was insignificantly decreased 1.7-fold at this point. Depolarization with KCl induced similar but less pronounced effects in LN229 (Figure 2 A,B) . In contrast, SV-FHAS cells only responded to depolarization with KCl whereas no significant increase was detected after NMDA stimulation. Cell viability was not influenced in a relevant manner by the experimental conditions at each time point (data not shown). at maximum ( Table 1) .
Glioblastoma cells express the NMDA receptor
NMDA receptors are functionally active in LN229 glioma cells
In order to determine the effect of NMDA treatment on the regulation of intracellular Ca 2+ activity, we treated LN229 cells with 10 µM NMDA. This treatment is known to accelerate Ca 2+ entry. The Fura-2 fluorescence ratio (340/380 nm) in the presence of extracellular Ca 2+ was significantly lower before NMDA treatment (4.04 ± 0.37, n = 4) than after NMDA treatment (6.56± 0.32, n = 4) (Figure 4) . These results show that the astrocytic tumor cell possess functionally active NMDA receptors.
The nuclear expression of EGR-1 in human astrocytic tumors in vivo is strongly associated with NMDA receptor expression
Immunofluorescent staining (n = 5 glioblastomas) showed that EGR-1 expression in human glioblastomas was restricted to the nucleus ( Figure 5A ). In double staining experiments, nuclear EGR-1 protein was mainly seen in cells strongly co-expressing the NMDA-R on the cell surface ( Figure 5B ).
EGR-1 is significantly upregulated in human astrocytomas compared to normal CNS tissue
In normal CNS tissue, classical immunohistochemistry revealed that about 9.4% (CI:
6.7-12.5%) of all glial cells expressed EGR-1. In comparison to normal brain, all grades of astrocytic tumor displayed significantly higher EGR-1 levels. EGR-1 expression was mainly found within the nuclei but occasionally also in the cytoplasm (Figure 6A, B) . Figure 6A, B) .
EGR-1 expression is significantly associated with enhanced patient survival in high grade astrocytomas and an independent prognostic factor in multivariate analysis
As WHO grade III and IV astrocytomas showed no significant differences of EGR-1 expression, a combined survival analysis was performed. The exponential parametric survival fit revealed a highly significant positive association of EGR-1 expression and patient survival in high grade astrocytic tumors (p=0.007) ( Figure 7A) . In a KaplanMeier analysis where EGR-1 expression levels were split by median, the log rank test also demonstrated significantly longer survival rates for the group exhibiting higher EGR-1 expression levels ( Figure 7B) . In WHO grade II astrocytomas, the exponential parametric fit did not show a significant association of EGR-1 levels and patient survival (p=0.43). In the group of WHO grade I astrocytoma only one patient died, therefore pilocytic astrocytomas were not included in survival analysis. A multivariate analysis performed in high grade astrocytomas included EGR-1 expression, patient age and WHO grade, which are both known to be strong predictors for patient survival in human astrocytomas, as well as gender, Karnofsky score, tumor localisation, extent of resection and edema score ( Table 2) red: low EGR-1 expression level; n = 130).
